“It was the closest I ever came to dying.”
17 October 2026
Ireland
A guest's account of nearly dying during gender-related medical treatment is the starting point for this episode of Beyond Gender. From an Irish angle, the story raises a plain question: what safety nets exist here when something goes wrong at a gender clinic? This piece sets out the actual Irish rules — informed consent duties under Medical Council guidance, the HSE's National Gender Service pathway, the 2024 pause on new puberty blocker prescriptions following the Cass Review, and where adverse events are supposed to be reported, to HIQA or the HPRA.
This episode of Beyond Gender centres on a guest's first-hand account of a medical crisis so severe they describe it as the closest they came to dying, connected to treatment they received as part of their gender transition. Hosts Stella O'Malley, Mia Hughes and Dr Bret Alderman use the story to press a question that gender-critical commentators have raised for years: when treatment for gender dysphoria goes badly wrong, who is accountable, and what warning systems exist to catch the problem before it reaches crisis point. The episode does not name an Irish setting, and the facts of the particular case are the guest's own. What can be checked from Ireland is the framework that would apply if a similar complication happened here. The HSE's National Gender Service, run out of St Columcille's Hospital in Loughlinstown, is the main public pathway for adults seeking hormone treatment or referral for surgery, and it operates under an informed consent model rather than a lengthy psychiatric assessment process. The Medical Council's guide to professional conduct requires doctors to give patients enough information about risks, benefits and alternatives before any treatment begins, and that duty applies in full to hormone therapy and surgical referral. For minors, the picture has shifted recently. Following the publication of the Cass Review in England in April 2024, the HSE paused the prescription of puberty blockers to new patients under eighteen at the National Gender Service pending its own clinical review, a decision that followed years of campaigning from clinicians and parents questioning the evidence base for paediatric transition. That pause remains one of the clearest points of Irish policy directly shaped by the wider evidence debate that Beyond Gender regularly covers. When something does go wrong, Ireland has two separate channels that matter. Adverse reactions to medicines, including hormone preparations, can be reported to the Health Products Regulatory Authority, which maintains a public database of reported reactions. Complaints about the standard of care at a health service, including gender services, fall under HIQA's remit for monitoring health and social care, alongside the Medical Council's fitness-to-practise process for complaints against individual doctors. Neither system is built specifically around gender medicine, and no Irish body currently publishes aggregated data on complications arising from transition-related treatment, a gap that leaves patients largely reliant on individual case reports rather than a tracked safety record. That gap is precisely why personal testimony like the guest's carries weight beyond one individual's experience. Without routine, specific reporting on outcomes from gender-affirming treatment, episodes like this one function as an informal early warning system, surfacing problems that official statistics in Ireland are not yet structured to capture. For parents, GPs and therapists trying to weigh real risk against reassurance, the existence of these formal reporting routes, and their current limits, is as relevant as the story itself.
